The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial by Carrington, Rhys et al.
RESEARCH Open Access
The influence of dose distribution on
treatment outcome in the SCOPE 1
oesophageal cancer trial
Rhys Carrington1*, Emiliano Spezi2, Sarah Gwynne3, Peter Dutton4, Chris Hurt4, John Staffurth5
and Thomas Crosby5
Abstract
Purpose: The first aim of this study was to assess plan quality using a conformity index (CI) and analyse its influence
on patient outcome. The second aim was to identify whether clinical and technological factors including planning
treatment volume (PTV) volume and treatment delivery method could be related to the CI value.
Methods and materials: By extending the original concept of the mean distance to conformity (MDC) index, the
OverMDC and UnderMDC of the 95 % isodose line (50Gy prescribed dose) to the PTV was calculated for 97 patients
from the UK SCOPE 1 trial (ISCRT47718479). Data preparation was carried out in CERR, with Kaplan-Meier and multivariate
analysis undertaken in EUCLID and further tests in Microsoft Excel and IBM’s SPSS.
Results: A statistically significant breakpoint in the overall survival data, independent of cetuximab, was found with
OverMDC (4.4 mm, p < 0.05). This was not the case with UnderMDC. There was a statistically significant difference in
PTV volume either side of the OverMDC breakpoint (Mann Whitney p < 0.001) and in OverMDC value dependent on
the treatment delivery method (mean IMRT = 2.1 mm, mean 3D-CRT = 4.1 mm Mann Whitney p < 0.001). Re-planning
the worst performing patients according to OverMDC from 3D-CRT to VMAT resulted in a mean reduction in OverMDC
of 2.8 mm (1.6–4.0 mm). OverMDC was not significant in multivariate analysis that included age, sex, staging, tumour
type, and position.
Conclusion: Although not significant when included in multivariate analysis, we have shown in univariate analysis that
a patient’s OverMDC is correlated with overall survival. OverMDC is strongly related to IMRT and to a lesser extent with
PTV volume. We recommend that VMAT planning should be used for oesophageal planning when available and that
attention should be paid to the conformity of the 95 % to the PTV.
Introduction
In the UK, oesophageal cancer is the sixth most common
cause of cancer, accounting for around 5 % of all cancer
deaths [1]. Long term survival for operable squamous cell
carcinomas treated with definitive chemoradiotherapy
(dCRT) is comparable to surgery alone [2], and is also
more effective than either radiation therapy or chemother-
apy alone [3, 4]. It is clear that radiotherapy (RT) now
plays a key role in the treatment of these tumours, how-
ever the formulation and application of optimal RT proto-
cols to these sites is not well defined [5]. There is a clear
need however to improve the quality and outcome of
therapy. It is known that dose distribution is an important
factor when evaluating the quality of RT plans. A de-
cisive parameter when considering the acceptability of a
plan is whether 95 % of the prescribed (tumoricidal)
dose is delivered to 100 % of the planning target vol-
ume (PTV) [6, 7]. However, although this requirement
will be met in the majority of patients undergoing RT,
the quality of the dose distribution may vary according
to factors such as PTV volume [8] or by the delivery
technique [9]. It has been shown that adherence to a
site-specific RT protocol is effective in improving plan
quality and patient outcomes [10], and the SCOPE 1
trial (a National Cancer Research Institute and Cancer
Research UK funded Phase II/III two arm trial of dCRT
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with and without cetuximab in oesophageal cancer
[11]) provided a detailed RT study protocol and quality
assurance programme [12].
SCOPE 1 showed low rates of acute and late toxicity
with 50 Gy in 25 fractions over 5 weeks concurrent
with chemotherapy [13]. Two-year overall survival was
56 % in the control arm, higher than previously re-
ported in published studies; However, no benfit was
seen for the addition of Cetuximab in the experimen-
tal arm.
Despite a detailed radiotherapy protocol and planning
guidance document, a rigorous Radiotherapy Treat-
ment Trials Quality Assurance (RTTQA) programme
[14, 15] demonstrated variation in RT planning practice
such as planning technique across the 34 UK centres
that participated in this study. These factors may have
affected the quality of the dose distribution achieved
for each patient, in addition to those mentioned previ-
ously. A recent study by Mutic et al. noted that many
plans may still be classed as ‘low quality’ even when ad-
hering to clinical trial protocol [16].
We hypothesised that plan quality can be objectively
assessed by quantifying the relationship between the
95 % isodose and the PTV using a conformity index
(CI) and explored the effect of variation in these mea-
sures on patient outcome (in this case the survival data
from the SCOPE 1 trial). The use of conformity indices
to analyse dose distribution of RT plans has been
carried out previously [17, 18]. However, to the best of
our knowledge, this study is the first to explore the
relationship of CI and patient outcome.
The aim of this study was two fold; Firstly to assess plan
quality using a CI and analyse its influence on patient out-
come. Secondly, to identify whether clinical and techno-
logical factors including PTV volume and treatment
delivery method could be related to the CI value.
Materials and methods
Study workflow
This study’s key stages are shown in Fig. 1. The follow-
ing section gives an in depth account of how the data
was gathered, a suitable database created and the ana-
lysis undertaken.
Data preparation and analysis
SCOPE1 has been ethically approved by the Research
Ethics Committee for Wales and has approval from the
Medicines and Health Care Product Regulatory Agency
to be conducted in the UK. The RTTQA programme for
the SCOPE 1 trial required centres to submit 3D dose
and structure data in DICOM RT format for of all
patients treated within the trial to the Wales Cancer
Trials Unit (WCTU). We imported and processed this
data into the CERR software package (Computational
Environment for Radiotherapy Research) [19]. Previous
work from our institution found that the dose distribu-
tion within a RT plan is algorithm dependent [14] and
that plan optimization carried out with algorithms that
model lateral electron transport results in improved
PTV coverage. These algorithms have been classified as
“Type B”. Of the 206 patients in the SCOPE 1 trial, 97
were planned with Type B algorithms and form the data-
set for this study.
We ensured the integrity of the database by checking
that the gross tumour volume (GTV), PTV, organs at
risk (OAR) and dose maps were present and re-named
to a pre-defined convention to allow automated ana-
lysis. This was also important in facilitating comparison
of dosimetry across patient databases in any future ana-
lyses [20]. Due to the size of the database, work was
undertaken within the group to develop and enhance
Matlab based scripts from previous published work
from this group [15] to automatically process and
amend the database to ensure the required uniformity.
The 95 % isodose line for each patient was created and
converted to a structure, V95%, using a Matlab script
based in CERR.
Plan quality metric
Conformity indexes are mathematical methods of quan-
tifying the conformity of one volume with respect to an-
other and several methods are available. A review of
these methods was undertaken by Feuvret et al. [21] in
which the advantages and disadvantages of a number of
CIs in the context of the analysis of dose distribution are
described. The Mean Distance to Conformity (MDC)
index was first introduced by Jena et al. [22] to compare
RT target volume delineation by different observers. For
a specific volume that is being evaluated against a refer-
ence volume, the MDC represents the average distance
that all outlying points in the volume must be moved in
order to achieve perfect conformity with the reference
Fig. 1 Workflow showing different stages of study
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volume. According to Jena, MDC provides (a) a single
scoring statistic that represents the overall conformity of
the two volumes being assessed, (b) additional statistics
that provide information on whether the non-conformity
is caused by over or under outlining and (c) a method of
display that facilitates evaluation of the clinical signifi-
cance of discrepancies.
Here we extend the application of MDC to dose distri-
bution, by quantifying the conformity of the 95 % isodose
line to the PTV. In our approach, the two components of
the metric, OverMDC and UnderMDC, allow both ‘over-
dosing’ of normal tissues and ‘underdosing’ of the PTV
respectively, to be objectively measured.
For the PTV and V95%, the MDC calculates the aver-
age distance that the furthermost outlying point of the
evaluation volume (V95%) would have to be moved in
order to conform exactly to that of the reference volume
(PTV). This results in two metrics that give a measure-
ment of the over and under coverage of the PTV by the
V95%, known as OverMDC and UnderMDC respectively.
These were calculated between the V95% and PTV for
each patient.
Statistical analysis
Data analysis was undertaken in EUCLID, an outcome
analysis tool for high-dimensional clinical studies based
in Matlab [23], Microsoft Excel [24] and IBM’s Statistical
Package for the Social Sciences (SPSS) [25].
Kaplan-Meier plots were generated to observe whether
there was a threshold for the CI value in relation to sur-
vival. Outcome data for each patient, including overall
survival, was collated and prepared by the WCTU. Rates
of late toxicity were so low that further analysis of nor-
mal tissue effects were not pursued. Due to the adverse
effect of cetuximab on survival in the SCOPE 1 trial
[13], the cetuximab administration data for each patient
was also acquired to allow for stratification.
Using the EUCLID package, comparisons of survival
of two populations discriminated by a given variable
(OverMDC and UnderMDC) was performed using a log
rank test of the hypothesis that the curves describe the
same survival function.
A function was used in EUCLID that allows the option
to scan the range of the variable (in this case OverMDC
and UnderMDC) to find the break point value that yields
the lowest p-value and therefore best separates the low
survival from the high survival population. This is cor-
rected for multiple comparisons using the Bonferroni
adjustment, a method of dealing with multiple testing
when finding an optimal break point [26]. Cox propor-
tional hazard, Mann-Whitney tests and stratification for
cetuximab was undertaken in SPSS. Pearson tests were
undertaken in Microsoft Excel.
Effect of dose delivery method
In order to evaluate the impact of treatment delivery, we
re-planned patients from 3D-conformal to Volumetric
Modulated Arc Therapy (VMAT) in Oncentra OMP
using a class solution, the hypothesis being that VMAT
would improve the dose conformity. The class solution
was developed to provide a clinically acceptable plan for
the majority of patients using the VMAT technique. Any
patient plans that would not meet the SCOPE 1 RT dose
volume constraints following re-planning with the class
solution would be adjusted manually. The dose volume
constraints for the PTV and OARs were the same for
every patient in the SCOPE 1 trial regardless of the dose
delivery technique used (See Table 1).
Multivariate analysis
Multivariate logistic regression analysis was undertaken
in EUCLID using the method described by Gayou et al.
[23]. The clinical variables attributable to all patients
included in the analysis in addition to the cetuximab
randomisation were; age, sex, tumour type (squamous
cell or adenocarcinoma), tumour stage (1–4), tumour
site (upper, mid, lower third), PTV volume, disease
length, UnderMDC and OverMDC.
Results
OverMDC and UnderMDC and overall survival
For the 97 patient plans in this study, the median
OverMDC was 3.7 mm (Range: 1.2–7.0 mm). The
break point occurs at an OverMDC value of 4.4 mm
with p = 0.02 (logrank) and results in a 28 above/69
below split in the database (Fig. 2).
The Cox Proportional Hazard ratio was calculated in
SPSS to be 0.50 (95 % CI: 0.28–0.90, p = 0.02).
Stratifying for cetuximab administration, the log rank
test between the two groups gave p = 0.04.
Therefore within this cohort, the OverMDC value
for the conformity of the 95 % isodose line and the
PTV for any particular patient is a predictor for over-
all survival in univariate analysis, independent of
Table 1 Dose volume constraints in SCOPE 1 trial
Region of interest/Organ at risk Dose constraint
PTV V95 % (47.5Gy) > 99.0 %
PTV PTV min > 93 % (46.5Gy)
DMAX <107 %
GTV GTV min > 100 % (50.0Gy)
Spinal cord PRV Cord Max <80 % (40Gy)
Combined lungs V40 % (V20Gy) < 25 %
Heart V80 % (V40Gy) < 30 %
Liver V60 % (V30Gy) < 60 %
Individual kidneys V40 % (V20Gy) < 25 %
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cetuximab administration; a high OverMDC is associ-
ated with worse survival.
UnderMDC
The median UnderMDC was 2.5 mm (Range: 0–5.7 mm).
The break point occurs at an UnderMDC value of 2.7 mm
with a p = 0.05 (logrank) and results in a 32 above/62
below split in the database (Fig. 3).
The Cox Proportional Hazard ratio was calculated in
SPSS to be 0.53 (95 % CI: 0.30–0.97, p = 0.04).
Stratifying for cetuximab administration, the log rank
test between the two groups gave p = 0.14. Therefore
UnderMDC cannot be considered a statistically signifi-
cant predictor for overall survival when stratifying for
cetuximab.
Analysis of OverMDC values
As only OverMDC remained clinically and statistically
significant following stratification for cetuximab, further
analysis was limited to this metric. The aim was to iden-
tify factors that may influence the OverMDC calculated
for each patient.
PTV volume and OverMDC
Figure 4 shows the PTV volume for each patient plot-
ted with OverMDC values, ranked by increasing
OverMDC value, with the line of best fit for the PTV
volumes. There was a significant difference in PTV vol-
ume either side of the OverMDC breakpoint of 4.4 mm
(Mann-Whitney p < 0.001). The Pearson coefficient be-
tween the OverMDC metric and PTV volume was cal-
culated to be 0.47.
IMRT/VMAT dose delivery
Patients were classified according to whether the treat-
ment dose in the SCOPE 1 trial was delivered via 3D
conformal (81 patients) or IMRT/VMAT treatment
(16 patients).
Figure 3 therefore also illustrates a statistically signifi-
cantly lower OverMDC value if the patient was treated
using IMRT/VMAT (Filled markers) compared to 3D-
CRT (mean IMRT = 2.1 mm, 3D-CRT = 4.1 mm; Mann
Whitney p < 0.001). There was no significant difference
in PTV volume according to the treatment delivery
method (Mann Whitney p = 0.455).
Re-planning of 3D-CRT plans
The result in the previous section show the OverMDC
values for 97 patients planned and treated with different
treatment modalities. In order to confirm that only the
treatment modality was influencing the OverMDC value,
the 15 worst performing patients according to OverMDC
(plotted with square symbols in Fig. 4) were re-planned
from the 3D-CRT to VMAT in OMP. Ten patients
were successfully re-planned using the class solution
implemented in our centre. The five remaining patient
plans did not meet the SCOPE 1 protocol dose volumes
Fig. 2 Kaplan-Meier plot of OverMDC and overall survival
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constraints initially, but in all cases acceptable plans
were achieved after manual adjustment.
The OverMDC was reduced for all 15 patients after
replanning with VMAT (Fig. 5), with a mean reduction
of 2.8 mm (Range: 1.6–4.0 mm). This confirms that the
treatment modality has a large influence on OverMDC
value. However there are also two outliers where the
OverMDC was not reduced to the same extent. On
further review it was found that these two patients had
an above average PTV volume (441 cm3 and 498 cm3)
when compared to the SCOPE 1 database mean PTV
volume (334 cm3). The average PTV volume for the re-
planned patients was 393 cm3.
Multivariate analysis
OverMDC and UnderMDC were included in a multi-
variate logistic regression analysis along with other clin-
ical factors. They were, age, sex, tumour type, tumour
stage, tumour site, cetuximab administration, PTV vol-
ume and disease length. It was found that none of these
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factors were statistically significant. The factors with the
lowest p-values were found to be age and tumour sta-
ging (p = 0.06 and p = 0.08 respectively).
Discussion
The aim of this study was firstly to quantify plan quality
using a CI and its effect on patient outcome. Secondly,
to identify whether clinical and technological factors in-
cluding PTV volume and treatment delivery method
could be related to the CI value.
We found that OverMDC has a statistically significant
relationship with overall survival in univariate analysis in-
dependent of cetuximab administration, the latter having
been shown to adversely effect survival in the SCOPE 1
trial. We have also shown that PTV volume was weakly
correlated with the OverMDC value of each patient
(Pearson’s correlation – 0.47), but the treatment delivery
method had a more significant impact with the mean
IMRT OverMDC being 51 % of the mean 3D-CRT
OverMDC value. When OverMDC and UnderMDC were
included with other clinical variables in a multivariate
logistic regression analysis neither remained significant.
The volume of the PTV may have an influence on dose
coverage. Meeting constraints for larger PTVs is more dif-
ficult due to the likely increased overlap with organs at
risk (OAR). Specifically in the case of oesophageal cancer,
OARs such as the heart, lungs and spinal cord are in close
proximity to the oesophagus and may limit the ability to
optimise the dose distribution. In this study we hypothe-
sized that a larger PTV volume would be associated with
an increase in OverMDC and UnderMDC values due to
the increased complexity of the resulting RT plan and
ability to conform the dose to the PTV due to the need to
spare adjacent OARs. Statistical tests showed that there
was indeed a significant difference in the PTV volumes
of patients either side of the OverMDC break point. No
significant difference was found in the case of the
UnderMDC metric.
This study also confirmed that IMRT and VMAT in-
crease dose conformity when compared to 3D-conformal
therapy, as shown elsewhere in the literature [27]. This is
demonstrated by the significantly smaller OverMDC
values between the V95% and PTV volumes in the IMRT/
VMAT patients of the SCOPE 1 trial and furthermore by
the re-planning of the worst performing patients by
OverMDC value from 3D-conformal to VMAT. A study
in gastric cancers found similar results when comparing
3D-conformal radiotherapy to IMRT [28], concluding that
a better target coverage and therefore significant dose
reduction to OARs could be achieved in IMRT plans. It is
clear therefore that the more conformal dose delivery
techniques should be used to administer RT wherever
possible.
The explanation for the improved overall survival in pa-
tients treated with a lower OverMDC value more con-
formal treatment is not clear. The association with IMRT/
VMAT treatment is interesting as only 3 centres treated
the 16 patients with IMRT/VMAT in the original trial. In
addition Fig. 5 clearly shows two cases where re-planning
with VMAT/IMRT did not reduce the OverMDC value to
the same extent, but their PTV volume was higher than
the average for the patients included in this study. It is
possible that low OverMDC and/or access to IMRT/
VMAT reflect other aspects of a high quality RT process
that require further investigation in a future study. It is
also fully acknowledged that when the OverMDC metric
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is included in a multivariate analysis that includes other
common factors in cancer treatment, it does not remain
statistically significant. Furthermore, there was no re-
corded grade 3 or 4 toxicity for pneumonitis or of the
heart most commonly associated with radiotherapy of the
oesophageous in the SCOPE 1 trial. As a result, no mean-
ingful correlation between dose distribution and radio-
therapy induced toxicity can be made. It may be therefore
that the consequence of a plan’s OverMDC value on over-
all survival is a combination of a number of factors that
require further investigation outside the scope of this par-
ticular study.
Nevertheless, this study suggests that IMRT/VMAT
offers a safe tool for dose escalation, as the MDC ana-
lysis has shown that unnecessary irradiation of normal
tissue can be significantly reduced without affecting
PTV coverage. This is consistent with the findings of
Freilich and Chun et al. [29, 30] who concluded that al-
though the use of IMRT did not directly impact on sur-
vival, it was associated with significantly less toxicity.
Warren et al. also showed that IMRT allows dose escal-
ation to 60Gy with the same level of normal tissue ir-
radiation as 3D-CRT to 50Gy [8]. This is being taken
forward in the recently funded SCOPE 2 trial. Unfortu-
nately there were an insufficient number of patients
treated with IMRT/VMAT in this study to detect any
impact on survival. In addition, patients treated with
IMRT/VMAT may have been expected to have a lower
rate of toxicity, however the rates were so low within the
SCOPE 1 trial that this could not be studied.
In a clinical setting, the results of this study suggest
that careful attention to the quality of RT planning,
expressed in terms of conformity of the dose distribution
to the target volume, may impact on overall survival.
IMRT/VMAT should be considered for all patients when
conforming the 95 % isodose to the PTV is difficult.
Conclusion
We have shown using a CI that in univariate analysis the
quality of a plan with respect to PTV coverage has a sig-
nificant correlation with overall survival. Plan quality is
strongly related to the use of advanced RT delivery tech-
niques and to a lesser extent with PTV volume. A CI may
therefore be useful in assessing plan quality and we rec-
ommend careful attention to all aspects of PTV coverage.
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